Text Size

Plasma Citrulline Level in Relation to Absorptive Surface

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT00286039
First received: February 1, 2006
Last updated: September 29, 2011
Last verified: September 2011
History of Changes
  Purpose

Correlation between determination of citrulline in plasma or dried blood

Reference ranges for healthy children and babies

Longitudinal follow-up of citrulline in preterm babies


Condition Intervention
Intestinal "Failure"
 Procedure: Blood sampling

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Plasma Citrulline Level in Relation to Absorptive Surface

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Correlation between determination of citrulline in plasma or dried blood [ Time Frame: Untill end of study ] [ Designated as safety issue: No ]
  • Reference ranges for healthy children and babies [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • Longitudinal follow-up of citrulline in preterm babies [ Time Frame: Untill end of study ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: August 2005
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Blood sampling
    Blood sampling is used.
  Eligibility

Ages Eligible for Study:   up to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 0-18 years
  • preterm babies up to 1.500g
  • preterm babies over 1.500g

Exclusion Criteria:

  • gastro-intestinal problems (except for the preterm babies)
  • congenital metabolic disorders
  • dysfunction of the liver or kidneys
  • congenital defects
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00286039

Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Investigators
Principal Investigator: Eddy Robberecht, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
Website University Hospital Ghent  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT00286039     History of Changes
Other Study ID Numbers: 2005/163
Study First Received: February 1, 2006
Last Updated: September 29, 2011
Health Authority: Belgium: Institutional Review Board

ClinicalTrials.gov processed this record on May 19, 2013